financetom
Business
financetom
/
Business
/
Update: Nvidia Fiscal Q3 Non-GAAP Earnings, Revenue Rise; Q4 Outlook Set
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Update: Nvidia Fiscal Q3 Non-GAAP Earnings, Revenue Rise; Q4 Outlook Set
Nov 20, 2024 7:41 PM

05:02 PM EST, 11/20/2024 (MT Newswires) -- (Updates the stock change in the last paragraph.)

Nvidia ( NVDA ) reported fiscal Q3 non-GAAP earnings late Wednesday of $0.81 per diluted share, up from $0.40 a year earlier.

Analysts polled by FactSet expected $0.75 excluding some items.

Revenue in the three months ended Oct. 27 rose to $35.08 billion from $18.12 billion a year earlier.

Analysts surveyed by FactSet expected $33.17 billion.

The company expects fiscal Q4 revenue of $37.5 billion, plus or minus 2%. Analysts expect $37.09 billion.

Nvidia ( NVDA ) shares fell 0.7% in after-hours activity, paring earlier losses.

Price: 144.81, Change: -1.08, Percent Change: -0.74

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
WhiteHawk Income Prices Upsized IPO of 7.7 Million Shares for NYSE Listing
WhiteHawk Income Prices Upsized IPO of 7.7 Million Shares for NYSE Listing
Jun 9, 2026
04:23 AM EDT, 06/09/2026 (MT Newswires) -- WhiteHawk Income ( WHK ) priced an upsized initial public offering of 7.7 million shares of Class A common stock at $26.00 each. The offering represents an upsizing of 775,000 shares, the company said late Monday. WhiteHawk granted underwriters a 30-day option to purchase up to about 1.16 million additional shares. Shares are...
Eli Lilly Enters Licensing Deal With AlzeCure Pharma for Alzheimer's Drug Candidate
Eli Lilly Enters Licensing Deal With AlzeCure Pharma for Alzheimer's Drug Candidate
Jun 9, 2026
05:11 AM EDT, 06/09/2026 (MT Newswires) -- Eli Lilly ( LLY ) has entered into a collaboration and licensing agreement with AlzeCure Pharma for global rights to its Alzheimer's disease drug candidate Alzstatin ACD680, AlzeCure Pharma said Tuesday. Under the deal, AlzeCure Pharma said it will receive $10 million in upfront payment and milestone payments that could bring the total...
Factbox-Major deals involving US drugmakers and biotechs over the past decade
Factbox-Major deals involving US drugmakers and biotechs over the past decade
Jun 9, 2026
June 9 (Reuters) - GSK has agreed to buy cancer drug developer Nuvalent ( NUVL ) for $10.6 billion in its biggest deal in years, as the British drugmaker looks to bolster its pipeline and support long-term revenue growth. The move adds to a growing list of high-profile transactions over the past decade by U.S. pharmaceutical companies to acquire promising...
Market Chatter: BlackRock's New Space ETF to Incorporate IPOs in 10 to 30 Days
Market Chatter: BlackRock's New Space ETF to Incorporate IPOs in 10 to 30 Days
Jun 9, 2026
04:21 AM EDT, 06/09/2026 (MT Newswires) -- BlackRock ( BLK ) plans to launch the iShares Space Technologies UCITS ETF for European investors, allowing newly public companies to be incorporated within weeks of their listings, Bloomberg reported Tuesday. The index features an IPO fast-entry process, adding newly listed companies within 10 to 30 days. It also enables new listings to...
Copyright 2023-2026 - www.financetom.com All Rights Reserved